A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions

Healthy

Interventions

DRUG

ND-L02-s0201 Injection

Single IV infusion.

DRUG

Placebo

Single IV infusion.

Trial Locations (1)

Quintiles Phase One Services, LLC, Overland Park